Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Roivant Sciences $400 million at-the-market offering
We advised the company on an SEC-registered at-the-market offering
IDEAYA Biosciences $92 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Alnylam Pharmaceuticals $1.035 billion convertible senior notes offering
The 1% convertible notes are due 2027
Immunocore $250 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
Novo Nordisk $1.1 billion acquisition of Forma Therapeutics
We are advising Novo Nordisk on the transaction
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Blackstone and CPPIB $1.96 billion Advarra acquisition financing
We advised the lead arrangers and initial term lenders on the financing
Assertio $70 million convertible senior notes offering
The 6.5% notes are due 2027
Freeman Spogli investment in EverVet
We advised Tailwind Capital and EverVet on the transaction
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff